```html

Zollinger’s Disease (Gastric Hyperacidity) – A Complete Patient Guide

Overview

Zollinger’s disease, also called a gastrinoma, is a rare type of neuroendocrine tumor that arises from the G‑cells of the pancreas or duodenum. These tumors secrete excessive amounts of gastrin, a hormone that stimulates the stomach’s parietal cells to produce hydrochloric acid. The resulting gastric hyperacidity can lead to severe peptic ulcer disease, gastro‑esophageal reflux, and a range of systemic symptoms.

Although Zollinger‑Ellison syndrome (ZES) is the clinical manifestation of a gastrinoma, the term “Zollinger’s disease” is often used in patient‑focused literature to emphasize the hyperacidic component.

• Who it affects: Adults 30–60 years old; slight male predominance (≈55 %).
• Prevalence: Approximately 1–3 cases per million people worldwide, making it one of the rarest gastrointestinal tumors [1][2].
• Associated conditions: Up to 25 % of patients have Multiple Endocrine Neoplasia type 1 (MEN‑1), a hereditary syndrome that predisposes to pancreatic and duodenal tumors [3].

Symptoms

Symptoms stem from two main mechanisms: acidic damage to the gastrointestinal tract and the systemic effects of excess gastrin.

• Recurrent or refractory peptic ulcers – often multiple, distal to the duodenum, and resistant to standard ulcer therapy.
• Abdominal pain – crampy, epigastric pain that worsens 1–3 hours after meals when acid secretion peaks.
• Diarrhea – up to 40 % of patients; the high acid load inactivates pancreatic enzymes and harms intestinal mucosa, leading to steatorrhea and malabsorption.
• Heartburn and gastro‑esophageal reflux disease (GERD) – due to overwhelming acid exposure.
• Nausea / vomiting – especially after large meals.
• Weight loss – secondary to malabsorption, chronic pain, and decreased intake.
• Fatigue – from anemia (chronic blood loss) or malnutrition.
• Gastric ulcer bleeding – melena or hematemesis in severe cases.
• Gallstones – excess acid leads to cholesterol supersaturation in bile.
• Skin changes – rare hyperpigmentation or flushing due to high gastrin levels.

Symptoms may be intermittent, which often delays diagnosis.

Causes and Risk Factors

Zollinger’s disease is caused by the development of a gastrinoma. The precise trigger for tumor formation is not fully understood, but several risk factors have been identified:

• Genetic predisposition: MEN‑1 mutation (chromosome 11q13) accounts for ~25 % of gastrinomas.
• Family history of neuroendocrine tumors.
• Age: Incidence peaks between the fourth and sixth decades.
• Gender: Slight male predominance.
• Chronic H. pylori infection: May increase gastrin levels, but a direct causal link to gastrinomas is unproven.
• Smoking: Observational data suggest a modest increase in neuroendocrine tumor risk.

Diagnosis

Because symptoms overlap with common ulcer disease, a high index of suspicion is required, especially with refractory ulcers or ulcers distal to the duodenum.

Initial Evaluation

1. Medical History & Physical Examination – focus on ulcer history, MEN‑1 symptoms, and family history.
2. Laboratory Tests
   • Fasting serum gastrin level – a level > 1000 pg/mL strongly suggests ZES (sensitivity > 90 %).
   • Secretin stimulation test – gastrin levels rise paradoxically after secretin administration; a rise ≥ 120 pg/mL confirms gastrinoma.
   • Baseline gastric pH – < 2 confirms hyperacidity.
   • Complete blood count, iron studies, vitamin B12 – to assess anemia/malabsorption.

Imaging Studies

• Endoscopic ultrasound (EUS) – high resolution for small pancreatic/duodenal lesions.
• Multiphasic CT scan or MRI – evaluates tumor size, local invasion, and distant metastases.
• Somatostatin receptor scintigraphy (Octreoscan) or 68Ga‑DOTATATE PET/CT – most sensitive for detecting gastrinomas, especially those < 1 cm.

Pathology

If a lesion is surgically removed, histopathology confirms neuroendocrine differentiation (positive chromogranin A, synaptophysin) and grades the tumor by Ki‑67 index.

Treatment Options

Management aims to control acid hypersecretion, eradicate or control the tumor, and prevent complications.

Acid‑suppression Therapy (first line)

• Proton‑pump inhibitors (PPIs) – high‑dose omeprazole 60 mg or pantoprazole 80 mg daily, often divided twice daily. PPIs are the most effective agents; doses may need titration based on gastric pH.
• H2‑receptor antagonists – useful as adjuncts but less potent than PPIs.

Surgical Management

• Enucleation or segmental resection – preferred for solitary, non‑metastatic lesions.
• Pancreaticoduodenectomy (Whipple procedure) – indicated for larger or invasive tumors.
• Debulking surgery – for metastatic disease to reduce tumor burden and gastrin production.

Medical Therapy for Tumor Control

• Somatostatin analogs (SSA) – octreotide or lanreotide inhibit gastrin release and may shrink tumors; especially valuable in MEN‑1 or metastatic disease.
• Targeted therapies – everolimus (mTOR inhibitor) or sunitinib (tyrosine‑kinase inhibitor) in progressive, unresectable neuroendocrine tumors.
• Chemotherapy – limited role; used for high‑grade (G3) neuroendocrine carcinomas.

Management of Metastatic Disease

• Peptide receptor radionuclide therapy (PRRT) with ^177Lu‑DOTATATE has shown > 70 % disease control in gastrinomas expressing somatostatin receptors [4].
• Liver‑directed therapies (radiofrequency ablation, embolization) for hepatic metastases.

Lifestyle & Supportive Measures

• Avoid foods that stimulate acid (spicy, citrus, caffeinated beverages).
• Small, frequent meals to reduce gastric load.
• Stop smoking and limit alcohol, both of which increase acid secretion.
• Calcium and vitamin D supplementation if malabsorption is present.

Living with Zollinger’s Disease (Gastric Hyperacidity)

Long‑term control relies on a partnership between the patient, gastroenterologist, and endocrinologist.

• Medication adherence – PPIs must be taken exactly as prescribed; missing doses can cause rapid symptom recurrence.
• Regular monitoring – Serum gastrin and gastric pH are checked every 6–12 months; imaging (CT/MRI) annually or sooner if symptoms change.
• Nutrition – A registered dietitian can tailor a low‑acid, balanced diet; consider enzyme supplementation if steatorrhea persists.
• Psychosocial support – Chronic disease can cause anxiety; counseling or support groups (e.g., Neuroendocrine Cancer Association) are valuable.
• Vaccinations – If undergoing somatostatin analogs or immunosuppressive therapy, stay up‑to‑date on influenza, COVID‑19, and pneumococcal vaccines.

Prevention

Because most gastrinomas are sporadic, primary prevention is limited. However, risk reduction strategies include:

• Early genetic counseling and testing for individuals with a family history of MEN‑1.
• Eradication of Helicobacter pylori infection – while not proven to prevent gastrinomas, it reduces background ulcer disease and may lower diagnostic confusion.
• Smoking cessation and moderation of alcohol intake.
• Regular health checks for patients with MEN‑1 to detect endocrine tumors before they become symptomatic.

Complications

If left untreated or inadequately controlled, Zollinger’s disease can lead to serious health problems:

• Severe, refractory peptic ulcer disease – perforation, bleeding, or obstruction.
• Gastro‑esophageal reflux disease (GERD) complications – Barrett’s esophagus, esophageal adenocarcinoma.
• Malabsorption & nutritional deficiencies – iron, calcium, vitamin B12, leading to anemia, osteoporosis, and neuropathy.
• Metastatic disease – liver, lymph nodes, or bone spread, which worsens prognosis.
• Carcinoid syndrome – rare, but can occur when tumor secretes other hormones.
• Reduced quality of life – chronic pain, frequent hospital visits, and medication side effects.

When to Seek Emergency Care

---

References

1. National Institute of Diabetes and Digestive and Kidney Diseases. “Zollinger‑Ellison Syndrome.” NIH, 2023.
2. Mayo Clinic. “Gastrinoma (Zollinger‑Ellison syndrome).” Updated 2022.
3. Alhakim, A. et al. “MEN‑1 and Gastrinomas: Clinical Features and Management.” Journal of Clinical Endocrinology, 2021.
4. Kwekkeboom, D. et al. “Peptide Receptor Radionuclide Therapy for Neuroendocrine Tumors.” NEJM, 2020.
5. World Health Organization. “Neuroendocrine Tumors – WHO Classification.” WHO Press, 2022.

```